UMIN-CTR Clinical Trial

Basic information
Public title	A study to evaluate the anti-fatigue effect of plant extract material
Acronym	A study to evaluate the anti-fatigue effect of plant extract material
Scientific Title	A study to evaluate the anti-fatigue effect of plant extract material
Scientific Title:Acronym	A study to evaluate the anti-fatigue effect of plant extract material
Region	Japan

Condition
Condition	Healthy volunteers
Classification by specialty	Not applicable Adult
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	To examine the anti-fatigue effect of test food for 4 weeks
Basic objectives2	Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	VAS(fatigue sensation)
Key secondary outcomes	Chalder fatigue scale, POMS2 Japanese Adult Short version, OSA sleep inventory MA version, St. Mary's Hospital sleep questionnaire, Munich ChronoType questionnaire, autonomic nervous function evaluation, blood test, body weight, waist circumference, BMI

Base
Study type	Interventional

Study design
Basic design	Parallel
Randomization	Randomized
Randomization unit	Individual
Blinding	Double blind -all involved are blinded
Control	Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms	2
Purpose of intervention	Prevention
Type of intervention	Food
Interventions/Control_1	Intake of test food for 4 weeks
Interventions/Control_2	Intake of placebo for 4 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	20 years-old <=
Age-upper limit	65 years-old >=
Gender	Male and Female
Key inclusion criteria	1) Healthy males and females aged 20- 65 years 2) Subjects who perceive fatigue sensation in daily life 3) Subject whose BMI is 25 kg/m2 or more and less than 30 kg/m2 4) Subject whose HbA1c is 6.0 % or more and less than 6.5 % (for 10 people of each group) 5) Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent
Key exclusion criteria	1) Subjects with serious cardio-vascular, hepatic, renal, respiratory, endocrine or metabolic disorders or having a medical history of these disorders 2) Subjects with chronic fatigue syndrome (CFS) , or subjects deemed to have severe fatigue such as idiopathic chronic fatigue by the investigator 3) Subjects who take regularly pharmaceuticals or quasi-drugs which having the efficacy for recovery from fatigue or nutritional supplements during physical fatigue 4) Subjects who take regularly Foods with Function Claims labeled the effect of attenuating fatigue sensation 5) Subjects who have the possibility of developing allergic symptoms by the test food 6) Female subjects who are pregnant or lactating, or intending to become pregnant during the study 7) Subjects having blood sample of 200 ml or more taken within 1 month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood) 8) Subjects who took part in another study within 3 months prior to the start of the present study or who is currently taking part in another study 9) Subjects deemed unsuitable by the investigator
Target sample size	120

Research contact person
Name of lead principal investigator	1st name Satoshi Middle name Last name Inamasu
Organization	Kracie Holdings, Ltd.
Division name	R&D Innovation Group
Zip code	108-8080
Address	3-20-20, Kaigan, Minato-ku, Tokyo
TEL	070-3350-0767
Email	s.inamasu@kracie.co.jp

Public contact
Name of contact person	1st name Kota Middle name Last name Watanabe
Organization	Soiken Inc.
Division name	R&D Division
Zip code	560-0082
Address	Senri Life Science Center 13F, 1-4-2, Shinsenri-higashimachi, Toyonaka-shi, Osaka
TEL	06-6871-8888
Homepage URL
Email	watanabe_kota@soiken.com

Sponsor
Institute	Soiken Inc.
Institute
Department

Funding Source
Organization	Kracie Holdings, Ltd.
Organization
Division
Category of Funding Organization	Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization	IRB of Fukuda Clinic
Address	Shin-Osaka brick building 2F, 1-6- 1 Miyahara, Yodogawa-ku, Osaka-shi, Os aka
Tel	06-6398-0203
Email	fukudaclinicIRB@gmail.com

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2020 Year 10 Month 10 Day

Related information
URL releasing protocol
Publication of results	Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled	120
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status	Completed
Date of protocol fixation	2020 Year 08 Month 15 Day
Date of IRB	2020 Year 08 Month 15 Day
Anticipated trial start date	2020 Year 10 Month 10 Day
Last follow-up date	2020 Year 11 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date	2020 Year 09 Month 19 Day
Last modified on	2021 Year 03 Month 24 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000047735